Valencia

• An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Ended
  2023-508954-25-00 7 2022-05-11 Advanced solid tumors (squamous cell carcinoma of the head and neck (S
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended
  2023-508645-40-00 10 2022-05-10 Bullous Pemphigoid (BP)
• The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended
  2024-510872-18-00 4 2022-05-09 Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (
• An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult … Ended
  2024-515832-59-00 5 2022-05-03 Bullous Pemphigoid
• ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion Ended
  2023-508454-26-00 6 2022-05-01 Acute Ischemic Stroke
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended
  2023-508571-37-00 4 2022-04-29 Geographic atrophy (GA) secondary to Age-related Macular Degeneration
• Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended
  2023-504825-38-00 4 2022-04-15 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
• Open-label extesnion study of soticlestat in Dravet and Lennox-Gastaut Syndromes Ended
  2022-502802-34-00 5 2022-04-05 Dravet and Lennox-Gastaut Syndromes
• A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended
  2024-511560-93-00 5 2022-03-29 Schizophrenia
• Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended
  2023-508828-35-01 5 2022-03-28 Patients with advanced hormone receptor-positive/HER2- negative/HER2-E
• Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negat … Ended
  2024-511875-14-00 4 2022-03-24 Pre and post-menopausal women and men with unresectable locally advanc
• A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended
  2024-513304-33-00 5 2022-03-17 Type 1 diabetes mellitus
• A Phase 2 Trial of SCO-101 in combination with FOLFIRI for Patients with Metastatic Colorectal Cancer (mCRC) with acquired Resistance to FOL … Ended
  2024-518877-33-00 4 2022-03-17 Metastatic Colorectal Cancer
• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAM … Ended
  2023-508213-16-00 4 2022-03-15 Multiple Myeloma
• A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder. Ended
  2023-506511-17-00 4 2022-03-07 Binge eating disorder
• A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease Ended
  2024-512756-38-00 4 2022-02-17 Crohn`s Disease (CD)
• A study to evaluate the efficacy and safety of olorofim versus AmBisome® for treatment of invasive aspergillosis Ended
  2024-513030-38-00 5 2022-02-15 Invasive fungal infections due to Aspergillus spp.
• Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours Ended
  2024-511071-16-00 3 2022-02-10 Solid Tumours
• A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administ … Ended
  2024-514777-22-00 1 2022-02-07 Advanced Malignancies
• Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J … Ended
  2023-505457-40-00 5 2022-02-02 Previously Untreated Advanced Gastric or Gastroesophageal Junction Can
• Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended
  2024-514570-43-00 5 2022-01-24 Renal cell carcinoma
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503571-19-00 5 2022-01-20 Chronic Obstructive Pulmonary Disease (COPD)
• EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib … Ended
  2024-513023-17-00 5 2022-01-12 Treatment of acute graft-versus host disease (aGvHD) to the gastrointe

Showing 1,657–1,680 of 1,853 trials